Small nucleic acid therapy has become a research hotspot in the field of biomedicine because of its advantages of strong specificity, simple design, and a short development cycle.

Protheragen MedAI specializes in the development and scale-up production of advanced delivery systems for small nucleic acid therapeutics to drive innovation and change in medical technology. Our small nucleic acid delivery system focused on lipid nanoparticles (LNPs) and GalNAc conjugates was designed to optimize the efficacy and targeting of antisense oligonucleodes (ASOs), small interfering RNAs (siRNAs), and microRNAs (miRNAs).

LNPs

LNPS are highly versatile and are liposomes specifically optimized for nucleic acid drug delivery to encapsulate and protect these molecules from degradation. At Protheragen MedAI, we offer:

Formulation development

We designed and optimized LNP formulations to improve stability, encapsulation efficiency, and release characteristics. We optimized the formulation by selecting appropriate lipids, optimizing the ratio to nucleic acids, and adjusting the nanoparticle size and surface properties.

Flexible production solutions

We offer scalable production scales, transitioning from laboratory to industrial scale. We are equipped with advanced equipment for high-throughput production and quality control designed to ensure that LNPs meet regulatory standards.

Targeted delivery

We improved the specificity and effectiveness of small nucleic acid drug action by modifying LNPs or adding targeted ligands.

Stability and storage

The stability and shelf life of LNP formulations were improved by optimizing storage conditions and developing freeze-drying processes.

GalNAc Conjugates

GalNAc conjugates provide a powerful solution to small nucleic acids targeting the liver. Our services in the GalNAc delivery system cover the following areas:

Chemistry of coupling

We focused on investigating and optimizing the chemical coupling of GalNAc to small nucleic acids, ensuring the effectiveness of the ligation without affecting the biological activity of the drug. Our means of development include optimizing the conjugation process and improving the purity and functionality of the characterized conjugates.

Preclinical and clinical support

Our full range of services extends to preclinical development and clinical trial support, including a comprehensive evaluation of the pharmacokinetics, biodistribution, and therapeutic efficacy of GalNAc binding to small nucleic acids.

Scale of production

We provide scalable production solutions for Galnac-coupled drugs. Our facilities support mass production and strict quality control measures are in place to ensure the quality of our products.

Comprehensive R&D and Production Services

Our R&D and manufacturing services cover the entire life cycle of small nucleic acid delivery systems. We will work closely with our customers from initial formulation development through mass production and regulatory compliance.

• Innovative solutions
• Custom development
• Regulatory support
• Rapid delivery

Our delivery system is designed to solve the problems of poor targeting, serious off-target effects, and poor stability in the delivery of small nucleic acid drugs. We continue to invest in the development of advanced delivery systems to help our customers achieve precise and efficient delivery of small nucleic acid drugs.

At Protheragen MedAI, we are always committed to harnessing the power of AI technology to provide the most cutting-edge and effective solutions to advance the medical industry. Contact us today to explore the infinite possibilities of small nucleic acid therapy.